|
Neurodegenerative Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
The group of neurodegenerative diseases, Parkinson's disease (PD), dementia with Lewy bodies (DLB), and multiple system atrophy (MSA) all exhibit inclusions containing amyloid-type α-synuclein (α-syn) aggregates within degenerating brain cells.
|
31603909 |
2019 |
|
Neurodegenerative Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
Many neurodegenerative diseases are characterized by progressive loss of neurons and abnormal protein accumulation, including amyloid (A)β and tau in Alzheimer's disease and Lewy bodies and α-synuclein (α-syn) in Parkinson's disease (PD).
|
31055236 |
2019 |
|
Neurodegenerative Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
Parkinson's disease (PD) is the second most common neurodegenerative disease, the main pathological hallmark of which is the accumulation of α-synuclein (α-syn) and the formation of filamentous aggregates called Lewy bodies in the brainstem, limbic system, and cortical areas.
|
31031582 |
2019 |
|
Neurodegenerative Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
The α-synuclein is a major component of amyloid fibrils found in Lewy bodies, the characteristic intracellular proteinaceous deposits which are pathological hallmarks of neurodegenerative diseases such as Parkinson's disease (PD) and dementia.
|
30635607 |
2019 |
|
Neurodegenerative Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
The misfolding and aggregation of α-synuclein (αsyn) in the central nervous system is associated with a group of neurodegenerative disorders referred to as the synucleinopathies.
|
31064841 |
2019 |
|
Neurodegenerative Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
Parkinson's disease (PD) is a common neurodegenerative disease characterized pathologically by the selective loss of dopaminergic neurons in the substantia nigra and the intracellular accumulation of α-synuclein in the Lewy bodies.
|
29627340 |
2019 |
|
Neurodegenerative Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
Several aggregation-prone proteins such as the amyloid-beta (Aβ) peptides, tau proteins, and α-synuclein protein are involved in secondary pathogenic cascades initiated by a TBI and are also major building blocks of the hallmark pathological lesions in chronic human neurodegenerative diseases with dementia.
|
29933008 |
2019 |
|
Neurodegenerative Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
Alpha-synuclein (αSN) is an abundant presynaptic brain protein that its aggregated species believed to play pivotal roles in the development of neurodegenerative diseases, especially Parkinson's disease (PD).
|
30776494 |
2019 |
|
Neurodegenerative Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
Our findings represent a model for aSyn toxicity that has important implications for understanding synucleinopathies and other age-related neurodegenerative diseases.
|
30977294 |
2019 |
|
Neurodegenerative Disorders
|
0.400 |
AlteredExpression
|
group |
BEFREE |
We conclude that the effects of α-synuclein expression are substantially modified by the genetic background, illustrating that genetic background needs to be considered in C. elegans models of neurodegenerative disease.
|
30894116 |
2019 |
|
Neurodegenerative Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
In the past decade, a similar process has been associated with other proteins, such as Aβ, tau, and α-synuclein, which participate in other neurodegenerative diseases.
|
31123569 |
2019 |
|
Neurodegenerative Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
α-Synuclein is the major component of Lewy bodies and a candidate biomarker for neurodegenerative diseases in which Lewy bodies are common, including Parkinson's disease and dementia with Lewy bodies.
|
30125936 |
2019 |
|
Neurodegenerative Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
We measured Aβ40, Aβ42, total tau, phosphorylated-tau, and α-synuclein in CSF and plasma using matched samples from various neurodegenerative diseases to expand our basic knowledge on these biomarkers and their practical applications.
|
30814356 |
2019 |
|
Neurodegenerative Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
Our results suggested the initial step of the process by which α-Syn injures dopaminergic neurons and provides new therapeutic targets for α-Syn associated neurodegenerative disorders.
|
30776354 |
2019 |
|
Neurodegenerative Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
α-Synuclein (α-syn), a metabolite of neurons, induces glial activation and neuroinflammation and participates in pathogenesis of neurodegenerative diseases.
|
31098954 |
2019 |
|
Neurodegenerative Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
Recently, α-synuclein (α-syn) and its heterocomplexes with amyloid-β (Aβ) and tau have been suggested to be involved in the pathophysiological processes of neurodegenerative diseases.
|
30826968 |
2019 |
|
Neurodegenerative Disorders
|
0.400 |
GeneticVariation
|
group |
BEFREE |
The accumulation of intraneuronal inclusions containing misfolded alpha-synuclein (aSyn) within the central nervous system (CNS) is a common feature found in several neurodegenerative disorders including Parkinson's disease (PD).
|
30771169 |
2019 |
|
Neurodegenerative Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
α-Synuclein is strongly implicated in the pathogenesis of Parkinson's disease as well as in other neurodegenerative diseases.
|
30711526 |
2019 |
|
Neurodegenerative Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
Together, these results suggest that intracellular α-syn levels are regulated by lysosomal exocytosis in human dopaminergic neurons and may represent a potential therapeutic target for PD and other synucleinopathies.<b>SIGNIFICANCE STATEMENT</b> Parkinson's disease (PD) is the second most common neurodegenerative disease linked to the accumulation of α-synuclein (α-syn) in patient neurons.
|
31097622 |
2019 |
|
Neurodegenerative Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
Parkinson's disease (PD) is a progressive neurodegenerative disorder associated with the degeneration of dopamine neurons of the substantia nigra pars compacta (SNpc) and the presence of intra-neuronal aggregates of α-synuclein and its post-translational products.
|
30796974 |
2019 |
|
Neurodegenerative Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
Alpha-synuclein (AS), a 14 kDa synaptic protein associated with several neurodegenerative diseases, exists natively within erythrocytes (ERC).
|
31424413 |
2019 |
|
Neurodegenerative Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
As synucleinopathies, Parkinson's disease (PD) and multiple system atrophy (MSA) are neurodegenerative diseases that involve the spread of pathogenic alpha-synuclein (αSyn) throughout the brain.
|
31699323 |
2019 |
|
Neurodegenerative Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
In addition to reviewing the frequency of concomitant deposition of aSyn in the neurodegenerative proteinopathies, we also consider our current understanding of the interaction of aSyn with other neurodegenerative disease-associated proteins, including tau, TDP-43, amyloid-β and prion protein, in the context of neuropathologic studies describing the anatomical sites of potential concomitant pathology.
|
31508228 |
2019 |
|
Neurodegenerative Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
Parkinson's disease (PD) is a common neurodegenerative disorder involving α-synuclein (α-syn) aggregation, oxidative stress, dysregulation of redox metal homeostasis, and neurotoxicity.
|
31404721 |
2019 |
|
Neurodegenerative Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
α-Synuclein is a 140-amino acid protein produced predominantly by neurons in the brain which plays a role in the regulation of neurotransmitter release, synaptic function, and plasticity, thus making it the focus in understanding the etiology of a group of neurodegenerative diseases.
|
29959729 |
2019 |